Tuesday, October 18, 2022 9:55:20 AM
October 17 2022 - 05:19PM
GlobeNewswire Inc.
Alert
Share On Facebook
Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that two posters will be presented at the Infectious Disease Society of America’s IDWeek 2022.
The hybrid conference will be held from October 19-23 at the Walter E. Washington Convention Center in Washington, D.C. Posters will be available for registrants on the IDWeek Interactive Program and the IDWeek Mobile App starting on October 19, 8 a.m. ET. Onsite attendees can view posters from Oct. 20-22 from 8 a.m. to 6 p.m.
Data to be presented at IDWeek 2022 include:
Presentation Title: Impact of Asymptomatic Bacteriuria on Primary Efficacy Analyses in the Evaluation of Novel Antimicrobials for the Treatment of Patients with Urinary Tract Infection
Poster #: 227
Presenter: Steven Aronin
Time/Location: Thursday, October 20, 12:15 p.m. - 1:30 p.m. in Hall B+C
Presentation Title: Murine Efficacy Studies of Sulopenem Against Bacillus anthracis
Poster #: 1724
Presenter: Sailaja Puttagunta
Time/Location: Saturday, October 22, 12:15 p.m. - 1:30 p.m. in Hall B+C
These Posters will be made available on the Company’s website on the “Publications: Posters & Presentations” page under the “Our Science” tab once the conference ends.
About Iterum Therapeutics plc
Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.
Investor Contact:
Judy Matthews
Chief Financial Officer
312-778-6073
IR@iterumtx.com
Recent ITRM News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 11:30:38 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 11:15:13 AM
- Iterum Therapeutics Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/13/2024 11:00:00 AM
- Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024 • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem • GlobeNewswire Inc. • 04/29/2024 12:00:00 PM
- US Stock Futures Stable in Pre-Market On Path for Consecutive Quarterly Gains, Oil Prices Rise • IH Market News • 03/28/2024 11:42:00 AM
- Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/28/2024 11:00:00 AM
- Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024 • GlobeNewswire Inc. • 03/21/2024 08:30:00 PM
- Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat • GlobeNewswire Inc. • 03/15/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 01:16:14 PM
- Iterum Therapeutics Provides Business Update • GlobeNewswire Inc. • 03/06/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 10:00:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 12:15:32 PM
- Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections • PR Newswire (US) • 01/30/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/29/2023 09:30:15 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/14/2023 12:45:02 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/14/2023 12:30:02 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 12/04/2023 10:15:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/04/2023 10:00:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 01:30:09 PM
- Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule • GlobeNewswire Inc. • 12/04/2023 01:00:00 PM
- Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023 • GlobeNewswire Inc. • 11/07/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2023 01:00:11 PM
- Iterum Therapeutics Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections • GlobeNewswire Inc. • 10/24/2023 12:00:00 PM
- Iterum Therapeutics to Present Data at IDWeek 2023 • GlobeNewswire Inc. • 10/12/2023 01:15:00 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM